Nationwide Fund Advisors Cuts Holdings in Sucampo Pharmaceuticals, Inc. (SCMP)
Nationwide Fund Advisors lowered its position in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 76.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,608 shares of the biopharmaceutical company’s stock after selling 43,300 shares during the quarter. Nationwide Fund Advisors’ holdings in Sucampo Pharmaceuticals were worth $143,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Ameriprise Financial Inc. boosted its stake in Sucampo Pharmaceuticals by 1.3% in the second quarter. Ameriprise Financial Inc. now owns 131,790 shares of the biopharmaceutical company’s stock worth $1,384,000 after buying an additional 1,690 shares in the last quarter. Teachers Advisors LLC boosted its stake in Sucampo Pharmaceuticals by 2.9% in the second quarter. Teachers Advisors LLC now owns 68,499 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 1,953 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Sucampo Pharmaceuticals by 30.7% in the second quarter. Alliancebernstein L.P. now owns 38,362 shares of the biopharmaceutical company’s stock worth $403,000 after buying an additional 9,000 shares in the last quarter. HPM Partners LLC purchased a new stake in Sucampo Pharmaceuticals in the second quarter worth approximately $1,307,000. Finally, Systematic Financial Management LP purchased a new stake in Sucampo Pharmaceuticals in the second quarter worth approximately $1,648,000. 56.79% of the stock is owned by institutional investors and hedge funds.
In related news, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jason Patrick Meyenburg bought 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were acquired at an average price of $12.13 per share, with a total value of $48,520.00. Following the acquisition, the insider now owns 30,228 shares of the company’s stock, valued at $366,665.64. The disclosure for this purchase can be found here. 4.13% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/19/nationwide-fund-advisors-cuts-holdings-in-sucampo-pharmaceuticals-inc-scmp.html.
Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) opened at $10.55 on Friday. The firm has a market capitalization of $492.01, a P/E ratio of 7.23, a PEG ratio of 3.14 and a beta of 1.38. Sucampo Pharmaceuticals, Inc. has a 52 week low of $9.30 and a 52 week high of $17.55. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. The firm had revenue of $61.27 million during the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.30 earnings per share. sell-side analysts forecast that Sucampo Pharmaceuticals, Inc. will post 1.12 EPS for the current year.
SCMP has been the subject of several research reports. Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. TheStreet lowered Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research note on Wednesday, August 2nd. Leerink Swann initiated coverage on Sucampo Pharmaceuticals in a research note on Monday, August 21st. They issued an “outperform” rating and a $15.00 target price for the company. Roth Capital set a $30.00 target price on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Zacks Investment Research raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Tuesday, October 17th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Sucampo Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $16.00.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.